# Commission Regulation (EU) 2018/782 of 29 May 2018 establishing the methodological principles for the risk assessment and risk management recommendations referred to in Regulation (EC) No 470/2009 (Text with EEA relevance), Division II.6.6.1.2.2

Extent: E+W+S+N.I.

Guidance on the need for a pharmacological ADI as provided for in the Committee for Medicinal Products for Veterinary Use (‘CVMP’) guideline on the approach to establish a pharmacological ADI shall be followed. Where no pharmacological ADI is derived, justification for its absence shall be provided.

---
Source: https://www.legislation.gov.uk/eur/2018/782/annex/I/division/II/division/II.6/division/II.6.6/division/II.6.6.1/division/II.6.6.1.2/division/II.6.6.1.2.2 (the official version)
Page: https://openlegislation.uk/eu-regulation-2018-782/annex-I/division-II/division-II.6/division-II.6.6/division-II.6.6.1/division-II.6.6.1.2/division-II.6.6.1.2.2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

